Nevertheless, to evaluate those cases with any expression, we selected PD‐L1 expression of 1% and higher on tumor cells (TC) as a cut‐off based on the previous PD‐L1 IHC assays in CRC17 to ask whether this minor subset of mCRC might have a survival benefit. The gene discussed is CD274; the disease is neoplasm.